ARISAN THERAPEUTICS INC - TO CONDUCT NON-CLINICAL GOOD LABORATORY PRACTICE (GLP) IN VIVO GENOTOXICITY AND REPRODUCTIVE TOXICOLOGY AND GLP DEVELOPMENT AND REPRODUCTIVE (DART) TOXICOLOGY STUDIES.

PIID: 75N93023C00051Solicitation ID: HHS-NIH-NIAID-BAA2023-01

Signed Date: Nov 18, 2025Effective Date: Sep 22, 2023End Date: Closes in 258 days

Key Details

Dollars Obligated

$3.7M

Base & All Options

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

National Institutes of Health

NAICS Code

541715 - RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

CARLSBAD, CA, 920084401, CD-CA-49

Description

TO CONDUCT NON-CLINICAL GOOD LABORATORY PRACTICE (GLP) IN VIVO GENOTOXICITY AND REPRODUCTIVE TOXICOLOGY AND GLP DEVELOPMENT AND REPRODUCTIVE (DART) TOXICOLOGY STUDIES.

Contractor Information

Contractor: ARISAN THERAPEUTICS INC

UEI: PYRKTQPNVJZ8

CAGE Code: 616D2

Location: CARLSBAD, CA

Similar Awards

NCI OPERATIONAL TASK ORDER, FY26-FY27

LEIDOS BIOMEDICAL RESEARCH INC

$327.1M

MD NET

LEIDOS BIOMEDICAL RESEARCH INC

$163.5M

ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2)

LEIDOS BIOMEDICAL RESEARCH INC

$141.7M

AWARD OF THE BASE TO ST. JUDE FOR CEIRR CONTRACT 75N93021C00016. THIS CONTRACT WILL SUPPORT NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (CEIRR).

ST JUDE CHILDREN'S RESEARCH HOSPITAL INC

$103.3M

DOMESTIC INDUSTRIAL BASE EXPANSION OF KEY CHEMICALS FOR ACRYLONITRILE BUTADIENE RUBBER (NBR)

ASCEND PERFORMANCE MATERIALS TEXAS INC

$87.7M

View Full Record on USASpending.gov